Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Al Sharif, Ibtehaj ^a   Remmal, Adnane ^b   Aboussekhra, Abdelilah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Faculté des Sciences et Techniques de Fès   (Morocco)

Author keywords

Apoptosis; Breast cancer; E2F1; Eugenol; Survivin

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; EUGENOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MITOCHONDRIA; RECEPTORS, ESTROGEN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889967732     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-600     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Ca Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008, 83(1):26-36. 10.1038/sj.clpt.6100449, 18091763.
3. Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr med chem 2012, 19(23):3907-3921. 10.2174/092986712802002464, 3421454, 22788767.
4. Dona F, Chiodi I, Belgiovine C, Raineri T, Ricotti R, Mondello C, Scovassi AI. Poly (ADP-ribosylation) and neoplastic transformation: effect of PARP inhibitors. Curr pharm biotechnol 2012, Epub ahead of print.
5. Craig W, Beck L. Phytochemicals: health protective effects. Can J Diet Pract Res 1999, 60(2):78-84.
6. Craig WJ. Phytochemicals: guardians of our health. J Am Diet Assoc 1997, 97(10 Suppl 2):S199-204.
7. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 2005, 7(11-12):1630-1647.
8. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2002, 2(2):143-148. 10.1038/nrc723, 12635177.
9. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? a review of their clinical properties. Int J Cancer 2007, 120(3):451-458. 10.1002/ijc.22419, 17131309.
10. Pramod K, Ansari SH, Ali J. Eugenol: a natural compound with versatile pharmacological actions. Nat prod commun 2010, 5(12):1999-2006.
11. Benencia F, Courreges MC. In vitro and in vivo activity of eugenol on human herpesvirus. Phytother Res 2000, 14(7):495-500. 10.1002/1099-1573(200011)14:7<495::AID-PTR650>3.0.CO;2-8, 11054837.
12. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res 2006, 12(7 Pt 2):2337s-2341s.
13. Stich HF, Stich W, Lam PP. Potentiation of genotoxicity by concurrent application of compounds found in betel quid: arecoline, eugenol, quercetin, chlorogenic acid and Mn2+. Mutat Res 1981, 90(4):355-363. 10.1016/0165-1218(81)90058-6, 7335107.
14. Slamenova D, Horvathova E, Wsolova L, Sramkova M, Navarova J. Investigation of anti-oxidative, cytotoxic, DNA-damaging and DNA-protective effects of plant volatiles eugenol and borneol in human-derived HepG2, Caco-2 and VH10 cell lines. Mutat Res 2009, 677(1-2):46-52.
15. Ghosh R, Nadiminty N, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity. J Biol Chem 2005, 280(7):5812-5819.
16. Pisano M, Pagnan G, Loi M, Mura ME, Tilocca MG, Palmieri G, Fabbri D, Dettori MA, Delogu G, Ponzoni M, et al. Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol cancer 2007, 6:8. 10.1186/1476-4598-6-8, 1785384, 17233906.
17. Park BS, Song YS, Yee SB, Lee BG, Seo SY, Park YC, Kim JM, Kim HM, Yoo YH. Phospho-ser 15-p53 translocates into mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced apoptosis. Apoptosis 2005, 10(1):193-200. 10.1007/s10495-005-6074-7, 15711935.
18. Okada N, Hirata A, Murakami Y, Shoji M, Sakagami H, Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression by eugenol-related compounds. Anticancer Res 2005, 25(5):3263-3269.
19. Manikandan P, Murugan RS, Priyadarsini RV, Vinothini G, Nagini S. Eugenol induces apoptosis and inhibits invasion and angiogenesis in a rat model of gastric carcinogenesis induced by MNNG. Life Sci 2010, 86(25-26):936-941.
20. Al-Mohanna MA, Al-Khalaf HH, Al-Yousef N, Aboussekhra A. The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light. Nucleic Acids Res 2007, 35(1):223-233. 1802571, 17158160.
21. Rowlands TM, Pechenkina IV, Hatsell S, Cowin P. Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle 2004, 3(2):145-148.
22. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19(8):5785-5799. 84428, 10409765.
23. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999, 19(4):2690-2698. 84062, 10082535.
24. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8(1):61-70. 10.1038/nrc2293, 18075512.
25. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004, 279(39):40511-40520. 10.1074/jbc.M404496200, 15271987.
26. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13(2):293-325. 10.1677/erc.1.01172, 16728565.
27. Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U, et al. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 2007, 9(3):R33. 10.1186/bcr1681, 1929097, 17535433.
28. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat 2003, 82(1):11-16. 10.1023/B:BREA.0000003843.53726.63, 14672398.
29. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surgical oncology 2012, 21(2):125-131. 10.1016/j.suronc.2011.01.001, 21334875.
30. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010, 176(6):2911-2920. 10.2353/ajpath.2010.091125, 2877852, 20395444.
31. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7(12):683-692. 10.1038/nrclinonc.2010.154, 20877296.
32. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007, 19(6):649-657. 10.1016/j.ceb.2007.10.006, 2268988, 18032011.
33. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle?. Biochim Biophys Acta 2000, 1471(1):M43-56.
34. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1(8):639-649.
35. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002, 12(1):60-66. 10.1016/S0959-437X(01)00265-9, 11790556.
36. Stanelle J, Putzer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 2006, 12(4):177-185. 10.1016/j.molmed.2006.02.002, 16530485.
37. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
38. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003, 8(2):215-223. 10.1023/A:1025905008934, 14635796.
39. Haffner MC, Berlato C, Doppler W. Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia 2006, 11(1):63-73. 10.1007/s10911-006-9013-5, 16900390.
40. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007, 13(4):1076-1082. 10.1158/1078-0432.CCR-06-2221, 17317814.
41. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007, 29(1):19-35. 10.1002/biof.5520290103, 17611291.
42. Manikandan P, Vinothini G, Vidya Priyadarsini R, Prathiba D, Nagini S. Eugenol inhibits cell proliferation via NF-kappaB suppression in a rat model of gastric carcinogenesis induced by MNNG. Invest New Drugs 2011, 29(1):110-117. 10.1007/s10637-009-9345-2, 19851710.
43. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008, 55(3):165-176.
44. Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression. Oncology 2007, 73(1-2):112-117.
45. King TD, Suto MJ, Li Y. The wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012, 113(1):13-18. 10.1002/jcb.23350, 21898546.
46. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995, 55(4):949-956.
47. Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res 2006, 66(24):11649-11658. 10.1158/0008-5472.CAN-06-1645, 17178859.